Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Pembrolizumab & Renal Cell Carcinoma (RCC), the US Food and Drug Administration (FDA) has approved pembrolizumab for patients with renal cell carcinoma as adjuvant therapy at intermediate‑high or high risk of recurrence after nephrectomy, or after nephrectomy plus resection of metastatic lesions. This approval is based on the KEYNOTE‑564 trial, which showed a significant improvement in disease‑free survival vs placebo (1, 2)
The European Commission approved pembrolizumab as **…